Yes, Eliquis (apixaban) is a DOAC, which stands for direct oral anticoagulant. It belongs to a specific subclass called factor Xa inhibitors, meaning it directly blocks a key protein in the clotting process to prevent blood clots from forming. The FDA first approved it in 2012, and it has since become one of the most widely prescribed blood thinners in the United States.
What “DOAC” Actually Means
DOACs are a class of blood-thinning medications that work by directly targeting specific proteins in the clotting cascade. Older anticoagulants like warfarin work indirectly, interfering with vitamin K to slow down the production of several clotting factors at once. DOACs, by contrast, zero in on a single target. In the case of Eliquis, that target is factor Xa, a protein that plays a central role in converting inactive clotting material into the substance that actually forms clots.
You may also see DOACs referred to as NOACs (novel oral anticoagulants). The terms mean the same thing, though “DOAC” has become the preferred label since these drugs are no longer particularly novel.
What Eliquis Is Approved to Treat
Eliquis carries FDA approval for several conditions, all related to preventing or treating dangerous blood clots:
- Atrial fibrillation: Reducing stroke risk in people with nonvalvular atrial fibrillation, which is the most common reason it’s prescribed.
- Deep vein thrombosis (DVT) and pulmonary embolism (PE): Both treating active clots and preventing them from coming back after initial treatment.
- Post-surgical clot prevention: Reducing DVT risk after hip or knee replacement surgery.
How Eliquis Compares to Warfarin
The practical differences between Eliquis and warfarin are significant for daily life. Warfarin requires regular blood tests (INR testing) to make sure the dose is keeping your blood in the right range, and it interacts with many foods and medications. Vitamin K-rich foods like leafy greens can throw off warfarin’s effectiveness, which means careful dietary monitoring.
Eliquis doesn’t require routine blood monitoring and has far fewer food interactions. It also performs better at its primary job: a meta-analysis published in Cureus found that the risk of stroke or systemic embolism was 23% lower in patients taking apixaban compared to those on warfarin.
The tradeoff for years was that warfarin had a well-established reversal agent (vitamin K) for emergency bleeding, while Eliquis did not. That changed in 2018 when the FDA approved andexanet alfa, a reversal agent specifically designed for factor Xa inhibitors like Eliquis. It works by acting as a decoy protein that binds to the drug and neutralizes its blood-thinning effect. It’s recommended as the first-line reversal option for life-threatening or uncontrolled bleeding in patients on Eliquis.
Standard Dosing
Eliquis is taken orally twice a day, but the specific dose depends on the condition being treated. For atrial fibrillation, the standard dose is 5 mg twice daily. A lower dose of 2.5 mg twice daily is used for patients who meet at least two of three criteria: age 80 or older, body weight of 132 pounds (60 kg) or less, or a specific marker of reduced kidney function.
For treating an active DVT or PE, the starting dose is higher: 10 mg twice daily for the first seven days, then stepping down to 5 mg twice daily. For long-term prevention of recurrent clots after at least six months of treatment, the dose drops to 2.5 mg twice daily.
After hip replacement surgery, the typical course runs 35 days at 2.5 mg twice daily. After knee replacement, it’s shorter at 12 days.
Bleeding Risk
Because Eliquis works by reducing your blood’s ability to clot, bleeding is the most important side effect to be aware of. This can range from minor issues like bruising more easily or nosebleeds to more serious events like gastrointestinal bleeding. The 23% reduction in stroke risk compared to warfarin comes alongside a generally favorable bleeding profile, which is one reason Eliquis has become so widely used. Still, any unusual or prolonged bleeding while taking a DOAC warrants prompt medical attention, particularly since the reversal agent (andexanet alfa) may not be available at every hospital.